All three drugs are highly effective in improving progression-free survival (PFS) for patients with advanced HR+/HER2- breast cancer in combination with their indicated FDA combinations tamoxifen, fulvestrant, or aromatase Inhibitors (AIs) such as anastrozole and Letrozole (3–9). The gene discussed is CYP19A1; the disease is breast cancer.